CWICX
Price
$65.05
Change
-$4.55 (-6.54%)
Updated
Dec 17 closing price
RWIBX
Price
$64.43
Change
-$4.56 (-6.61%)
Updated
Dec 17 closing price
Ad is loading...

CWICX vs RWIBX

Header iconCWICX vs RWIBX Comparison
Open Charts CWICX vs RWIBXBanner chart's image
American Funds Capital World Gr&Inc 529C
Price$65.05
Change-$4.55 (-6.54%)
VolumeN/A
CapitalizationN/A
American Funds Capital World Gr&Inc R2
Price$64.43
Change-$4.56 (-6.61%)
VolumeN/A
CapitalizationN/A
CWICX vs RWIBX Comparison Chart
Loading...
View a ticker or compare two or three
VS
CWICX vs. RWIBX commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CWICX is a Buy and RWIBX is a Buy.

FUNDAMENTALS
Fundamentals
CWICX (130B) and RWIBX (130B) have equal amount of cash in the bank . RWIBX pays higher dividends than CWICX: RWIBX (1.05) vs CWICX (0.97). CWICX was incepted earlier than RWIBX: CWICX (23 years) vs RWIBX (23 years). CWICX (27.00) and RWIBX (27.00) have comparable annual turnover. CWICX (250) and RWIBX (250) have matching initial minimum investment requirements. CWICX (11.37) and RWIBX (11.34) have marching annual gain over last year. CWICX return over 5 years is better than : 32.23 vs. RWIBX (29.64).
CWICXRWIBXCWICX / RWIBX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence23 years23 years-
Gain YTD9.8269.781100%
Front LoadN/AN/A-
Min. Initial Investment250250100%
Min. Initial Investment IRAN/AN/A-
Net Assets130B130B100%
Annual Yield % from dividends0.971.0593%
Returns for 1 year11.3711.34100%
Returns for 3 years9.778.41116%
Returns for 5 years32.2329.64109%
Returns for 10 years57.0144.22129%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LITM0.180.03
+17.46%
Snow Lake Resources Ltd
NUVB2.810.12
+4.46%
Nuvation Bio
ENTG109.362.65
+2.48%
Entegris
ARQ7.01-0.04
-0.57%
Arq
PTCT47.02-1.59
-3.27%
PTC Therapeutics